Serum calprotectin as a potential biomarker for subclinical enthesitis in psoriatic patients

[1]  A. Radwan,et al.  The relationship of serum calprotectin with disease activity, functional status, ultrasonographic findings and radiological damage in rheumatoid arthritis patients , 2021 .

[2]  Ehsan K. Elsayed,et al.  Association of interleukin-17 with peripheral spondyloarthropathic changes detected by musculoskeletal ultrasound in psoriatic patients , 2020 .

[3]  M. Abdo,et al.  The incremental value of ultrasound in detection of subclinical peripheral enthesitis in patients with spondyloarthritis , 2020 .

[4]  H. Riahi,et al.  Plantar fascia enthesitis: Clinical, radiographic and ultrasound findings in patients with axial spondyloarthritis , 2020 .

[5]  D. Courvoisier,et al.  Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis , 2020, Arthritis Research & Therapy.

[6]  G. Kaeley.  Enthesitis in psoriatic arthritis (Part 2): imaging , 2020, Rheumatology.

[7]  M. Zaiss,et al.  A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations , 2020, Arthritis Research & Therapy.

[8]  M. Megna,et al.  Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study , 2019, The Journal of dermatological treatment.

[9]  H. Donia,et al.  Serum calprotectin as a predictive biomarker in the treatment of psoriasis vulgaris with methotrexate , 2019, Journal of the Egyptian Women's Dermatologic Society.

[10]  A. Gerards,et al.  Association of Physical Activity and Medication with Enthesitis on Ultrasound in Psoriatic Arthritis , 2019, The Journal of Rheumatology.

[11]  W. Hartung,et al.  Clinical assessment and ultrasonography in the follow-up of enthesitis in patients with spondyloarthritis: a multicenter ultrasound study in daily clinical practice , 2018, Open access rheumatology : research and reviews.

[12]  M. Gutierrez,et al.  Enthesitis: A hallmark of psoriatic arthritis. , 2018, Seminars in arthritis and rheumatism.

[13]  Nana Song,et al.  Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors. , 2018, European review for medical and pharmacological sciences.

[14]  A. Nast,et al.  Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials , 2018, The British journal of dermatology.

[15]  J. Hazes,et al.  Modification of a sonographic enthesitis score to differentiate between psoriatic arthritis and young healthy volunteers , 2018, Scandinavian journal of rheumatology.

[16]  H. Mann,et al.  Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study , 2017, PloS one.

[17]  P. Sarzi-Puttini,et al.  A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis. , 2017, Current Rheumatology Reviews.

[18]  L. Punzi,et al.  Calprotectin in rheumatic diseases , 2017, Experimental biology and medicine.

[19]  Philip J Mease,et al.  The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis , 2016, Arthritis & rheumatology.

[20]  J. Yagüe,et al.  Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity , 2016, Arthritis Research & Therapy.

[21]  J. Olesen,et al.  Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound. , 2016, Muscles, ligaments and tendons journal.

[22]  J. Pablos,et al.  Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission , 2016, Arthritis Research & Therapy.

[23]  Chun Li,et al.  Serum calprotectin—a promising diagnostic marker for adult-onset Still’s disease , 2015, Clinical Rheumatology.

[24]  Elżbieta Krzesiek.  Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children. , 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[25]  E. Güzel,et al.  Chemerin and calprotectin levels correlate with disease activity and inflammation markers in psoriasis vulgaris , 2015 .

[26]  D. Foell,et al.  MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. , 2015, Annals of the rheumatic diseases.

[27]  P. Oktayoğlu,et al.  Elevated Serum Levels of Calprotectin (Myeloid-Related Protein 8/14) in Patients With Ankylosing Spondylitis and Its Association With Disease Activity and Quality of Life , 2014, Journal of Investigative Medicine.

[28]  C. Eriksson,et al.  S-Calprotectin (S100A8/S100A9): A Potential Marker of Inflammation in Patients with Psoriatic Arthritis , 2014, Journal of immunology research.

[29]  R. Jonsson,et al.  Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren’s syndrome , 2014, Scandinavian journal of rheumatology.

[30]  E. Martı́n-Mola,et al.  Calprotectin in Rheumatoid Arthritis , 2013, Molecular Diagnosis & Therapy.

[31]  A. Anbar,et al.  Knee Enthesitis and Synovitis on Magnetic Resonance Imaging in Patients with Psoriasis without Arthritic Symptoms , 2012, The Journal of Rheumatology.

[32]  M. Sakaguchi,et al.  Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages. , 2011, Journal of the American Academy of Dermatology.

[33]  D. Foell,et al.  The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. , 2009, Arthritis and rheumatism.

[34]  P. Helliwell,et al.  Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. , 2008, Arthritis and rheumatism.

[35]  J. Brun,et al.  S100 proteins calprotectin and S100A12 are related to radiographic changes rather than disease activity in psoriatic arthritis with low disease activity. , 2007, The Journal of rheumatology.

[36]  W. Nacken,et al.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.

[37]  T. Vogl,et al.  Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. , 2003, Trends in immunology.

[38]  G. Hughes,et al.  Calprotectin in Patients with Systemic Lupus Erythematosus: Relation to Clinical and Laboratory Parameters of Disease Activity , 1993, Lupus.